Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC), either confirmed by a tissue biopsy or meeting specific imaging and blood test criteria set by a leading liver disease organisation (AASLD)
- People whose liver function falls into a category called "Child-Pugh stage A," which indicates relatively well-preserved liver function
- People where the portion of liver expected to remain after treatment is less than 40% of the total liver
- People with a general health and activity level rated as 0 or 1 on a standard scale (ECOG), meaning fully active or able to carry out light work
- People whose bilirubin (a liver-related chemical in the blood) is at or below 3.0 mg/dl — or higher if the treating doctor determines the tumour can be isolated from a vascular standpoint (confirm with trial site)
- People whose creatinine level (a kidney function marker) is at or below 2.0 mg/dl
- People whose white blood cell count (specifically neutrophils) is at or above 1.5 K/uL
- People whose platelet count is above 25 K/uL
- People who are willing to take part and have signed the consent form
- For Group 2 participants only: people whose planned treatment dose and embolic load fall within the optimal range identified from Group 1 data
Who may not be able to join:
- People who are pregnant
- Women who have had a menstrual period at any point in the last 12 months and have not had a hysterectomy or removal of both ovaries (confirm with trial site)
- For Group 2 participants only: people who have reasons they cannot undergo an MRI scan, including:
- People with severe claustrophobia who have not been able to tolerate an MRI in the past (note: people with mild claustrophobia may still be considered eligible)
- People with an allergy to gadolinium-based contrast dye used in MRI scans
- People with a pacemaker, certain metal clips, aneurysm clips, shrapnel, or similar metal objects in their body
- People with significantly reduced kidney function (eGFR below 30 mL/min/m²)
- People with serious, life-threatening disease outside the liver, or other active life-threatening cancers — including people on dialysis, those with ongoing serious infections, HIV, active hepatitis B or C, or unresolved severe diarrhoea
- People with conditions that prevent safe use of angiography (a procedure involving dye injected into blood vessels), such as uncontrollable bleeding or clotting disorders
- People with other serious health conditions that the treating doctor believes would make the treatment unsafe
- People with a history of severe allergic reactions or intolerance to contrast dye, sedatives, pain relief medications, or atropine that cannot be managed medically
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Robert Lewandowski, MD, Northwestern University
Phone: 312-695-9121
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Patient Group 1: Y90 Glass Microspheres; Patient Group 1: Sphere distribution; Patient Group 2: Quantitative Imaging Radiologic Biomarkers; Patient Group 2: HCC Resection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.